TCTMD

Verified
Online/Digital
TMD is the most comprehensive on-line resource in interventional cardiology and provides indepth coverage of the percutaneous treatment of cardiovascular disease. Since its launch at TCT 2000, TCTMD has provided clinicians and industry professionals myriad ways to keep up-to-date in the ever-evolving field, including news and data from conferences hosted around the world as well as information about the latest devices and drugs used in the daily practice of cardiovascular medicine. TCTMD is produced and administered by the Cardiovascular Research Foundation (CRF). CRF's mission is to strive to improve the quality of life for patients with cardiovascular disease. The organization's goal is to advance the development and use of safe and effective minimally invasive cardiovascular treatments. For more information, visit our Web site at http://www.crf.org. Source

Actions

Share this page

Media Outlet details

Scope National, Trade/B2B
Language English, Spanish
Country United States of America
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing

Recent Articles

Search

SAFER-TAVI: Radial Eases Secondary Access Site Problems

|
By Todd Neale Verified
| TCTMD Verified
News Conference News NY Valves 2026 The findings should lead to changes in practice, David Cohen says, but as seen in the setting of PCI, “old habits die hard.” NEW YORK, NY—Using the radial rather than the contralateral femoral artery for secondary access during TAVI seems to lessen the risks of bleeding and vascular complications at the secondary access site, according to results from the SAFER-TAVI trial.
Open in Who Shared Issue with article?

No Neuroprotective or Survival Benefits With Oxygen Restriction After Cardiac Arrest

|
By L.A. McKeown
| TCTMD Verified
The results were the same whether patients were enrolled earlier or later after return of circulation, the LOGICAL investigators say. In unresponsive patients hospitalized following cardiac arrest with suspected hypoxic ischemic encephalopathy (HIE), a conservative oxygen strategy does not improve survival or function compared with a liberal approach, the LOGICAL trial suggests.
Open in Who Shared Issue with article?

STUN-AF: Ablation Before LAAO May Reduce Peridevice Leaks

|
By Todd Neale Verified
| TCTMD Verified
News Conference News NY Valves 2026 The approach should be considered to prevent leaks, which have been tied to increased stroke risks, Vivek Reddy says. NEW YORK, NY—Among patients undergoing concomitant pulsed-field ablation (PFA) and left atrial appendage occlusion (LAAO) procedures for atrial fibrillation (AF) or flutter, ablating the appendage before LAAO may help reduce peridevice leaks, findings from the nonrandomized STUN-AF study suggest.
Open in Who Shared Issue with article?

Unlocking the Secrets of Speech Language Pathology

| TCTMD Verified
In the realm of human communication, speech language pathology stands as a vital discipline, dedicated to understanding and addressing the intricacies of language development, disorders, and rehabilitation. This fascinating field delves into the complexities of human expression, seeking to empower individuals with effective communication skills. At its core, speech language pathology focuses on the evaluation, diagnosis, and treatment of communication disorders and swallowing disorders.
Open in Who Shared Issue with article?

Calcium Modification Techniques Abound, With Lesion Prep Key to Success

|
By Yael L. Maxwell Verified
| TCTMD Verified
News Conference News EuroPCR 2026 Previously untreatable patients have several options, but preference, cost, and availability will guide which are used. PARIS, France—For once untreatable calcified coronary lesions, technologies have evolved to the point where clinicians now have several options to consider.
Open in Who Shared Issue with article?

IV Iron in HF: Mixed Data Haven’t Dashed Interest

|
By Caitlin Cox Verified
| TCTMD Verified
News Conference News ESC Heart Failure 2026 Experts at Heart Failure 2026 hashed out the lack of positive RCTs, why “function and feel” matter, and more. BARCELONA, Spain—Iron deficiency is common among patients with heart failure (HF), raising the possibility that addressing this need could improve prognosis. Experts at the recent Heart Failure 2026 meeting debated what’s holding the therapy back and how best to move forward in a way that optimizes outcomes, not just hard but soft endpoints, too.
Open in Who Shared Issue with article?

FUTURE-II Shines Bright for Bioresorbable Scaffold at 5 Years

|
By L.A. McKeown
| TCTMD Verified
News Conference News EuroPCR 2026 Panelists at EuroPCR agreed that with appropriate lesion and patient selection, BRS may be poised to enter a post-Absorb era. PARIS, France—A thinner-strut sirolimus-eluting bioresorbable scaffold (BRS) shows long-term results comparable to those achieved with contemporary DES for the treatment of noncomplex coronary lesions, according to additional follow-up from the FUTURE-II trial.
Open in Who Shared Issue with article?

Evolocumab Cuts MACE Risk in Stented Patients Without Prior MI VESALIUS-CV

|
By Michael O'Riordan Verified
| TCTMD Verified
News Conference News EuroPCR 2026 In this high-risk population, those who had a prior PCI had higher event rates but benefited from aggressive LDL-lowering. PARIS, France—Patients with atherosclerosis or high-risk diabetes who have undergone PCI, but who have not yet had an MI or stroke, fare significantly better when LDL-cholesterol levels are treated aggressively with a PCSK9 inhibitor, according to a new VESALIUS-CV analysis presented today at EuroPCR 2026.
Open in Who Shared Issue with article?

Inflammation Common in HF, No Matter the Ejection Fraction POSEIDON

|
By Caitlin Cox Verified
| TCTMD Verified
News Conference News ESC Heart Failure 2026 Anti-inflammatory therapies could prove helpful in this setting, but that’s yet to be seen. BARCELONA, Spain—Two in five patients with heart failure (HF) have high inflammatory risk, with a similar prevalence across the spectrum of ejection fraction, according to an international snapshot from the POSEIDON study.
Open in Who Shared Issue with article?

FDA Approves Baxdrostat for Inadequately Controlled Hypertension

|
By Todd Neale Verified
| TCTMD Verified
This is the first aldosterone synthase inhibitor to enter the US market. Baxdrostat (Baxfendy) has been approved by the US Food and Drug Administration for the treatment of patients with hypertension who have inadequately controlled blood pressure despite taking other antihypertensive medications, drugmaker AstraZeneca announced Monday.
Open in Who Shared Issue with article?

TCTMD Journalists

Cox, Caitlin
Maxwell, Yael L.
McKeown, L.A.
Neale, Todd
O'Riordan, Michael